First-in-class humanized monoclonal antibody targeting complement C2, blocking classical and lectin complement pathways upstream of C3/C5.
Dosing Notes
Investigational; IV administration in trials to date.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
Moderate ConfidenceSupported by limited controlled studies or consistent case series
Phase 3 registrational head-to-head trial of empasiprubart vs IVIg, currently active (not recruiting).
Verified Jul 2026
Clinical Trial Registry
EMPASSION: Phase 3 empasiprubart vs IVIg in adults with MMN — NCT06742190